The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

The partnership between the US military and the body and the non-profit will examine three drugs as potential therapies ...

MSD has commenced the Phase III trial to assess zilovertamab vedotin combined with R-CHP to treat individuals with previously ...

A total of 113 subjects were enrolled in the trial. Credit: SofikoS / Shutterstock. Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin ...